Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. More Details
+ 1 more risk
Flawless balance sheet and overvalued.
Share Price & News
How has Check-Cap's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CHEK's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: CHEK underperformed the US Medical Equipment industry which returned 13.7% over the past year.
Return vs Market: CHEK underperformed the US Market which returned 10.9% over the past year.
Price Volatility Vs. Market
How volatile is Check-Cap's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StHere's Why We're A Bit Worried About Check-Cap's (NASDAQ:CHEK) Cash Burn Situation
9 months ago | Simply Wall StWhat Kind Of Shareholder Appears On The Check-Cap Ltd.'s (NASDAQ:CHEK) Shareholder Register?
10 months ago | Simply Wall StHere's Why We're A Bit Worried About Check-Cap's (NASDAQ:CHEK) Cash Burn Situation
Is Check-Cap undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CHEK's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CHEK's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CHEK is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: CHEK is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CHEK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CHEK is good value based on its PB Ratio (0.6x) compared to the US Medical Equipment industry average (3.7x).
How is Check-Cap forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CHEK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CHEK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CHEK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if CHEK's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if CHEK's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CHEK's Return on Equity is forecast to be high in 3 years time
How has Check-Cap performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CHEK is currently unprofitable.
Growing Profit Margin: CHEK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CHEK is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.
Accelerating Growth: Unable to compare CHEK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CHEK is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).
Return on Equity
High ROE: CHEK has a negative Return on Equity (-90.99%), as it is currently unprofitable.
How is Check-Cap's financial position?
Financial Position Analysis
Short Term Liabilities: CHEK's short term assets ($16.9M) exceed its short term liabilities ($2.6M).
Long Term Liabilities: CHEK's short term assets ($16.9M) exceed its long term liabilities ($298.0K).
Debt to Equity History and Analysis
Debt Level: CHEK is debt free.
Reducing Debt: CHEK has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CHEK has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CHEK has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 14.5% each year.
What is Check-Cap current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CHEK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CHEK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CHEK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CHEK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CHEK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Alex Ovadia (58 yo)
Mr. Alex Ovadia has been Chief Executive Officer of Check-Cap Ltd since February 26, 2018 and serves as its Director. Mr. Ovadia was Vice President of Research & Development at Check-Cap Ltd. since joining ...
CEO Compensation Analysis
Compensation vs Market: Alex's total compensation ($USD502.02K) is about average for companies of similar size in the US market ($USD606.89K).
Compensation vs Earnings: Alex's compensation has been consistent with company performance over the past year.
|CEO & Director||2.58yrs||US$502.02k||0.0027% |
|Independent Director||5.5yrs||no data||0.0045% |
|Scientific Advisor||11.33yrs||no data||no data|
|Independent Director||5.33yrs||no data||0.0043% |
|Scientific Advisor||8.67yrs||no data||no data|
|Chairman of the Board||3yrs||no data||0.0045% |
|Independent Director||5.58yrs||no data||0.035% |
|Scientific Advisor||no data||no data||no data|
|Independent Director||3.25yrs||no data||0.0029% |
Experienced Board: CHEK's board of directors are considered experienced (5.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 461.2%.
Check-Cap Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Check-Cap Ltd.
- Ticker: CHEK
- Exchange: NasdaqCM
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$15.719m
- Shares outstanding: 46.23m
- Website: https://www.check-cap.com
Number of Employees
- Check-Cap Ltd.
- Check-Cap Building
- 29 Abba Hushi Avenue
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CHEK||NasdaqCM (Nasdaq Capital Market)||Yes||Ordinary Shares||US||USD||Mar 2015|
|7CC||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Mar 2015|
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and col ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/26 06:11|
|End of Day Share Price||2020/09/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.